NASDAQ:KURA Kura Oncology (KURA) Stock Price, News & Analysis $9.83 -0.57 (-5.48%) Closing price 04:00 PM EasternExtended Trading$9.90 +0.07 (+0.70%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Kura Oncology Stock (NASDAQ:KURA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kura Oncology alerts:Sign Up Key Stats Today's Range$9.76▼$10.2950-Day Range$9.20▼$13.5952-Week Range$7.36▼$13.90Volume2.71 million shsAverage Volume1.76 million shsMarket Capitalization$874.48 millionP/E RatioN/ADividend YieldN/APrice Target$25.69Consensus RatingModerate Buy Company Overview Kura Oncology, Inc. is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company uses molecular and genomic insights to identify therapies designed to target specific biological drivers of tumor growth. Kura’s lead program is ziftomenib, an oral menin inhibitor developed for genetically defined forms of acute myeloid leukemia, including disease associated with NPM1 mutations and KMT2A rearrangements. The company has also evaluated additional targeted oncology candidates, including therapies directed at the RAF-MEK-ERK signaling pathway. Founded in 2014 and headquartered in San Diego, California, Kura has conducted clinical development activities through research collaborations and studies involving patients and institutions in the United States and other regions. Its programs are intended to address cancers with significant unmet medical needs by matching targeted treatments to specific molecular characteristics.AI Generated. May Contain Errors. Read More Kura Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreKURA MarketRank™: 3.62781212998 of 5 starsKura Oncology scored higher than 73% of companies evaluated by MarketBeat, and ranked 241st out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingKura Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on no strong buy ratings, 11 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialKura Oncology has a consensus price target of $25.69, representing about 161.3% upside from its current price of $9.83.Amount of Analyst CoverageKura Oncology has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Kura Oncology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Kura Oncology are expected to grow in the coming year, from ($3.25) to ($2.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kura Oncology is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kura Oncology is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKura Oncology has a P/B Ratio of 4.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Kura Oncology's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.54% of the float of Kura Oncology has been sold short.Short Interest Ratio / Days to CoverKura Oncology has a short interest ratio ("days to cover") of 7.73.Change versus previous monthShort interest in Kura Oncology has recently decreased by 2.70%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKura Oncology does not currently pay a dividend.Dividend GrowthKura Oncology does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.55 News SentimentKura Oncology has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Kura Oncology this week, compared to 7 articles on an average week.Search InterestOnly 7 people have searched for KURA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Kura Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.1 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $642,817.00 in company stock, which represents 0.0735% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Kura Oncology insiders have bought 37.63% more of their company's stock than they have sold. Specifically, they have bought $2,351,000.00 in company stock and sold $1,708,183.00 in company stock.Percentage Held by Insiders7.60% of the stock of Kura Oncology is held by insiders.Percentage Held by InstitutionsKura Oncology has minimal institutional ownership at this time.Read more about Kura Oncology's insider trading history. Receive KURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KURA Stock News HeadlinesKura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript1 hour ago | seekingalpha.comCaspian Therapeutics, Kura Oncology Outline Development Path For Diabetes Candidate KO-7246October 13 at 2:17 PM | rttnews.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 13 at 1:00 AM | Banyan Hill Publishing (Ad)Kura Oncology, Inc. (KURA) Stock Price, News, Quote & History - Yahoo FinanceOctober 13 at 2:17 PM | finance.yahoo.comCaspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in DiabetesOctober 13 at 7:30 AM | globenewswire.comKura Oncology, Inc. (NASDAQ:KURA) Stock Has Average Price Target of $25.69 According to AnalystsOctober 11 at 2:29 AM | americanbankingnews.comKura Oncology (NASDAQ:KURA) Stock: Insider Kathleen Ford Sells 3,668 SharesSeptember 30, 2026 | insidertrades.comKura Oncology (NASDAQ:KURA) Stock: Insider Francis Burrows Sells 20,726 SharesSeptember 26, 2026 | insidertrades.comSee More Headlines KURA Stock Analysis - Frequently Asked Questions How have KURA shares performed this year? Kura Oncology's stock was trading at $10.39 at the beginning of the year. Since then, KURA shares have decreased by 5.4% and is now trading at $9.83. How were Kura Oncology's earnings last quarter? Kura Oncology, Inc. (NASDAQ:KURA) announced its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.11. The company earned $20.87 million during the quarter, compared to the consensus estimate of $20.16 million. Kura Oncology had a negative trailing twelve-month return on equity of 207.18% and a negative net margin of 384.30%. Read the conference call transcript. When did Kura Oncology's stock split? Kura Oncology's stock reverse split before market open on Friday, October 18th 2024.The 1-35 reverse split was announced on Monday, October 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Kura Oncology IPO? Kura Oncology (KURA) raised $90 million in an initial public offering (IPO) on Thursday, November 5th 2015. The company issued 14,279,820 shares at a price of $6.32 per share. How do I buy shares of Kura Oncology? Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kura Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kura Oncology investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Viking Therapeutics (VKTX), Palantir Technologies (PLTR), Micron Technology (MU) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings8/12/2026Today10/13/2026Investor update10/13/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 KURA's financial health is in the Green zone, according to TradeSmith. KURA has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KURA CIK1422143 Webwww.kuraoncology.com Phone(858) 500-8800FaxN/AEmployees260Year Founded2007Price Target and Rating Average Price Target for Kura Oncology$25.69 High Price Target$40.00 Low Price Target$15.00 Potential Upside/Downside+161.3%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($3.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$278.67 million Net Margins-384.30% Pretax Margin-384.19% Return on Equity-207.18% Return on Assets-45.17% Debt Debt-to-Equity Ratio0.12 Current Ratio4.73 Quick Ratio4.71 Sales & Book Value Annual Sales$67.48 million Price / Sales12.96 Cash FlowN/A Price / Cash FlowN/A Book Value$2.00 per share Price / Book4.92Miscellaneous Outstanding Shares88,960,000Free Float82,200,000Market Cap$874.48 million OptionableOptionable Beta0.47 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:KURA) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kura Oncology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
